Rewriting the cancer proteome: targeting selective translation as a therapeutic frontier

Davide Ruggero · 2026

Read Rewriting the cancer proteome: targeting selective translation as a therapeutic frontier by Davide Ruggero (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13262711.txt.

Description

Davide Ruggero writes a 2026 commentary on targeting protein production in cancer. Tumor studies often find that RNA levels poorly predict protein levels, so the making of proteins, called translation, helps set a cancer cell's identity. A study in the same journal issue blocked a key translation factor called eIF4E in prostate cancer.

Blocking eIF4E rewired which proteins the cancer cells made, the study found. It suppressed traits of the basal cell type, which resists hormone therapy, and pushed cells toward the luminal type, restoring hormone sensitivity. Ruggero argues that cancers broadly depend on selective translation to stay flexible and resist drugs. Attacking those dependencies could turn resistant cell states into treatable ones.

Catalog record

CREATORDavide Ruggero
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE14934
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13262711

Browse the full library · About the Tower of Babel